LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention

Preeclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide. Low-dose aspirin started in the first trimester reduces the risk of preeclampsia in high-risk women. Low molecular weight heparin (LMWH) has shown potential benefits in addition to aspirin for preventing preeclampsia through its anticoagulant, anti-inflammatory, and endothelial protective effects. However, current evidence is limited and conflicting regarding the added value of LMWH to aspirin. This randomized controlled trial aims to evaluate the efficacy of combined aspirin and LMWH, compared to aspirin alone, for reducing the incidence of preeclampsia in high-risk gravidas.

NCT Number	NCT07361679
Lead Sponsor	Alexandra Hospital, Athens, Greece
Conditions	Preeclampsia Severe, Toxemia Of Pregnancy, Preeclampsia, Pregnancy Complications, Hypertension, Pregnancy-Induced, Gestational Hypertension
Enrollment	100 participants
Start Date	2023-01-18
Primary Completion	2026-08-01 (estimated)
Study Completion	2027-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-23